Randomized clinical trials (CONSORT);Ensayos clínicos aleatorizados (CONSORT)

Medicina Clinica

Volumn 125, Issue SUPPL. 1, 2005, Pages 21-27

  Cobos Carbó, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Guidelines; Publishing standards; Quality assurance; Randomized controlled trials standards

Indexed keywords

ARTICLE; HEALTH CARE; HEALTH CARE QUALITY; INTERPERSONAL COMMUNICATION; MEDICAL LITERATURE; PROFESSIONAL PRACTICE; PUBLICATION; SCIENTIST;

AUTHORSHIP; CHECKLIST; PERIODICALS AS TOPIC; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH REPORT; SOFTWARE DESIGN;

EID: 33845987598     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/s0025-7753(05)72205-3     Document Type: Article

References (85)

1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-12.
2. Kjaergård L, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy [Abstract]. In: Abstracts for Workshops and Scientific Sessions, 7th International Cochrane Colloquium, Rome, 1999.
3. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol. 2000;136:381-5.
4. Kjaergård LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology. 1999;30:1134-8.
5. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med. 1982;306:1332-7.
6. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272:122-4.
7. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670-4.
8. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA. 1994;272:125-8.
9. Gore SM, Jones IG, Rytter EC. Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. Br Med J. 1977;1:85-7.
10. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med. 1987;317:426-32.
11. Altman DG. The scandal of poor medical research [editorial]. BMJ. 1994;308:283-4.
12. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA. 1994;272:1926-31.
13. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Ann Intern Med. 1994;121:894-5.
14. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637-9.
15. Campbell MK, Elbourne DR, Altman DG, for the CONSORT Group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:702-8.
16. Moher D, Altman DG, Schulz KF, Elbourne DR. Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. CMAJ. 2004;171:349-50.
17. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. The CONSORT Group. JAMA. 2001;285:1992-5.
18. Egger M, Jüni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. The CONSORT Group. JAMA. 2001;285:1996-9.
19. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA. 1998;279:1487-9.
20. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. The CONSORT Group. Ann Intern Med. 2001;134:657-62.
21. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. The CONSORT Group. JAMA. 2001;285:1987-91.
22. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. The CONSORT Group. Lancet. 2001;357:1191-94.
23. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94.
24. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286-91.
25. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-6.
26. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-54.
27. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol. 1998;51:69-79.
28. Roberts C. The implications of variation in outcome between health professionals for the design and analysis of randomized controlled trials. Stat Med. 1999;18:2605-15.
29. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed. New York: Oxford Univ Pr; 1996.
30. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249-52.
31. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ. 1998;317:1191-4.
32. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994;121:200-6.
33. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics. 1987;43:213-23.
34. Pocock SJ. When to stop a clinical trial. BMJ. 1992;305:235-40.
35. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med. 1985;4:521-6.
36. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does [editorial]. BMJ. 1998;317:362-3.
37. Martyn C. Not quite as random as I pretended. BMJ. 1996;347:70.
38. Williams DH, Davis CE. Reporting of assignment methods in clinical trials. Control Clin Trials. 1994;15:294-8.
39. Schulz KF. Subverting randomization in controlled trials. JAMA. 1995;274:1456-8.
40. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med. 1987;6:315-28.
41. Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Information Journal. 1998;32:11.
42. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology. 1994;44:16-20.
43. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17:285-90; discussion 290-3.
44. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Guyatt GH. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285:2000-3.
45. Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH. Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:245-52.
46. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry. 2000;157:327-37.
47. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. En: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with Confidence: Confidence Intervals and Statistical Guidelines. 2nd ed. London: BMJ Books; 2000. p. 171-90.
48. Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997;314:1874.
49. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol. 1998;38:408-12.
50. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000;29:158-67.
51. Kerry SM, Bland JM. Analysis of a trial randomised by clusters. BMJ. 1998;316:54.
52. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064-9.
53. Altman DG. Adjustment for covariate imbalance. En: Armitage P, Colton T, editors. Encyclopedia of Biostatistics. Chichester: John Wiley; 1998. p. 1000-5.
54. Matthews JN, Altman DG. Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ. 1996;313:808.
55. Altman DG. Randomisation [editorial]. BMJ. 1991;302:1481-2.
56. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410-2.
57. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation. 1981;64:669-73.
58. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet. 1990;335:149-53.
59. Senn S. Base logic: tests of baseline balance in randomized clinical trials. Clinical Research and Regulatory Affairs. 1995;12:171-82.
60. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med. 1991;10:1595-605.
61. Lachin JL. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21:526.
62. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med. 2000;19:1849-64.
63. ICH E9. Statistical principles for clinical trials, february 1998 [accedido el 20 de Julio 2005]. Disponible en: http://www.ich.org
64. Chadwich D. Monotherapy comparative trials: equivalence and differences in clinical trials. Epilepsy Res. 2001;45:101-3.
65. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36-9.
66. Brittain E, Lin D. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials. Stat Med. 2005;24(1):1-10.
67. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986; 292:746-50.
68. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern Med. 1997;126:36-47.
69. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. Applied Statistics. 2000;49:359-70.
70. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med. 2000;19:3325-36.
71. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485.
72. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 «negative» trials. N Engl J Med. 1978;299:690-4.
73. Luus HG, Muller FO, Meyer BH. Statistical significance versus clinical relevance. Part II. The use and interpretation of confidence intervals. S Afr Med J. 1989;76(11):626-9.
74. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064-9.
75. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
76. Ioannidis JP, Lan J. Completeness of safety reporting in randomized trials. An evaluation of 7 medical areas. JAMA. 2001;285:437-43.
77. Horton R. The rhetoric of research. BMJ. 1995;310:985-7.
78. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. JAMA. 1998; 280:227-8.
79. Docherty M, Smith R. The case for structuring the discussion of scientific papers [editorial]. BMJ. 1999;318:1224-5.
80. Information for authors. Annals of Internal Medicine [accedido el 22 Julio 2005]. Disponible en: http://www.annals.org
81. Schwartz D, Flamant R, Lellouch J. L'essai thérapeutique chez l'homme. Flammarion Médecine-Sciences; 1970.
82. Roland M, Torgerson DJ. Understanding controlled trials: what are pragmatic trials? BMJ. 1998;316:285.
83. Davey Smith G, Egger M. Who benefits from medical interventions? [editorial]. BMJ. 1994;308:72-4.
84. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA. 1998;279:545-9.
85. Gøtzsche PC, Gjørup I, Bonne'n H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ. 1995;310:1495-8.